SecBot SecBot
8-K ·Filed Apr 16, 2026

ENZND

Viskase Holdings, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago SEC0001104659-26-044420
8-K material event: Items 4.01
Actionable Insight • Neutral

Monitor for any future filings that might reveal additional context about the auditor change, particularly since it follows a merger. The appointment of Grant Thornton, who previously audited Viskase, suggests continuity in auditing approach.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d
ENZND ▲ +5.18% at T+20d
NEUTRAL call +5.18% · α vs SPY -0.20% · entry $5.99 → $6.30
Next anchor: T+60d due 4mo ago
Entry = T+0 close
Apr 16, 2026
via day close
T+1d
-4.84%
call -4.84% · α -4.65%
$5.70
settled 6mo ago
T+5d
+10.89%
call +10.89% · α +10.34%
$6.64
settled 6mo ago
T+20d
+5.18%
call +5.18% · α -0.20%
$6.30
settled 6mo ago
T+60d
Pending
due 4mo ago

Price Chart

Loading chart...

Executive Summary

Viskase Holdings, Inc. changed its independent registered public accounting firm, appointing Grant Thornton LLP as the new auditor and dismissing EisnerAmper LLP. This change follows the company's recent merger and name change from Enzon Pharmaceuticals, Inc. to Viskase Holdings, Inc.

Key Facts

  • Grant Thornton LLP was appointed as the new independent registered public accounting firm for the fiscal year ending December 31, 2026
  • EisnerAmper LLP was dismissed as the company's independent registered public accounting firm
  • The change follows the company's merger and name change from Enzon Pharmaceuticals, Inc. to Viskase Holdings, Inc.
  • Grant Thornton served as the independent registered public accounting firm of Viskase prior to the merger
  • There were no disagreements with EisnerAmper on accounting principles, financial disclosure, or auditing scope

Financial Impact

No immediate financial impact disclosed

audit feesaccounting expenses

Risk Factors

  • Potential for increased audit fees with new accounting firm
  • Transition risks during change of auditors

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-044420
Document: tm2611998d1_ex16-1.htm0001104659-26-044420
Document: 0001104659-26-044420-index-headers.html0001104659-26-044420
Document: 0001104659-26-044420-index.html0001104659-26-044420
Document: 0001104659-26-044420.txt0001104659-26-044420
2 reports for ENZND
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ENZND — sortable, filterable
TypeNow
Apr 21, 2026
26w ago
8-K
BEARISH ★ 6/10
$6.83 $5.75▲ +15.78%▲ +18.94%—
Apr 16, 2026
27w ago
8-K
NEUTRAL ★ 3/10
$5.99 $6.30▲ +5.18%▼ −0.20%—
Showing 2 of 2

US Market Status

Market Closed — Opens Wed (17h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 16, 2026